Q4 2025 Myasthenia Gravis Market: FDA Approvals, Campaigns, and Patient Support Initiatives 

Immunovant emphasized batoclimab learnings to support IMVT-1402 development with a focus on autoinjector-based access.

Merck received the FDA Fast Track and Orphan Drug designations for cladribine and advanced patient-directed and digital health initiatives.

UCB promoted the “Reach Higher” campaign for Rystiggo alongside patient initiatives, such as the Myasthenia Gravis Scholarship program.

Amgen announced the FDA approval of Uplizna and promoted the “Do More” campaign supported by treatment access and education resources.